Related Experiment Video
Updated: Jan 9, 2026
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Structured Personalized Oxygen and Supportive Therapies for Dyspnea in Oncology (SPOT-ON): A personalized randomized
David Hui1,2,3, Min Ji Kim1, Saji Thomas4
1Department of Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Background:
Low-flow supplemental oxygen (LFSO), high-flow nasal cannula (HFNC), and non-invasive ventilation (NIV) are often used for palliation of dyspnea in hospitalized patients. However, it is unclear how patients prefer to use these modalities and how they can be personalized for optimal dyspnea relief. The objective of this randomized clinical trial is to compare the effect of a personalized respiratory therapist (RT)-led intervention, termed SPOT-ON, and enhanced usual care on dyspnea intensity in both hypoxemic and non-hypoxemic hospitalized patients with cancer.
Methods:
In this two-arm, parallel group, partially blinded, waitlist-controlled randomized clinical trial, hospitalized patients with advanced cancer and at least moderate dyspnea intensity at rest (numeric rating scale [NRS] ≥4/10) will be randomized 1:1 to receive SPOT-ON immediately or after a 72-hour waiting period. The SPOT-ON intervention consists of a time-limited trial of LFSO, HFNC, and NIV for 10 minutes each, followed by personalized deployment of these modalities to tailor device settings and timing and duration of use based on patient preference over 72 hours. The waitlist control group will receive structured dyspnea education after enrollment and usual care. The primary outcome will be change in dyspnea NRS intensity from baseline to 24 hours. Secondary outcomes include dyspnea unpleasantness, vital signs, symptom burden, health-related quality of life, adverse events, pattern of device use, and hospital outcomes. We calculated that 150 patients (75 hypoxemic and 75 non-hypoxemic) will provide 80% power to detect a 1.2-point difference between groups with α = 0.025, assuming a standard deviation of 1.5 and 20% attrition.
Discussion:
Successful completion of this clinical trial could inform the use of oxygen and supportive modalities to reduce dyspnea. This novel personalized clinical trial methodology involving time-limited trials to tailor therapy based on patient preferences may inform the design of future supportive care clinical trials.
Trial Registration:
Clinicaltrials.gov NCT06336642.
Related Concept Videos
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:16Oxygen Delivering System II: Venturi Mask and Transtracheal Oxygen
Venturi Mask
The Venturi mask, named after the Venturi effect, is designed to deliver precise oxygen concentrations. It consists of a large tube with an oxygen inlet that narrows down, causing a pressure drop that pulls air in through adjustable side ports. The mask is a lightweight,...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:30Administering Oxygen by Mask
Administering oxygen by mask is a common nursing intervention that provides supplemental oxygen to patients with respiratory distress or chronic lung conditions. This procedure involves delivering oxygen at a specified rate through a face mask connected to an oxygen source.
Equipment
The equipment necessary for this procedure includes:
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...